Pacini identified comma-shaped organisms termed vibrios in the gastrointestinal contents of corpses of cholera victims, hypothesizing that these organisms were responsible for the copious intestinal fluid secretion characteristic of the disease, even proposing intravenous NaCl as a remedy [2, 6, 7] . These data unfortunately were not powerful enough to dislodge the prevailing "miasma" theory that cholera was transmitted by the foul air associated with poverty, overcrowding, and poor sanitation championed in particular by Max Joseph von Pettenkofer, an aristocratic Bavarian chemist and hygienist. Tragically, Pacini's data were overlooked for 30 years, until the eminent microbiologist Robert Koch was able to identify vibrio organisms in the intestines of those who succumbed to the disease and grow them in liquid culture [2, 8] .
The first published description of fluid resuscitation for cholera was published in 1831 by William B. O'Shaughnessy, who hypothesized that "…universal stagnation of the venous system, and rapid cessation of the arterialization of the blood, are the earliest, as well as the most characteristic effects." He proposed intravenous salt solutions, but not for their volume-expanding effects but for their oxygen content, recommending KNO 3 or KClO 3 as opposed to NaCl [9] . This practice was refined one year later by Dr. Thomas Latta and his collaborators located in the Leith Cholera Hospital in Scotland as well as in other institutions in the UK, who initiated the practice of infusing massive amounts of saline solution, with resultant immediate recovery of intravascular volume and symptom improvement [10] ( Fig. 1 ). According to Robert Lewins, "The most wonderful and satisfactory effect is the immediate consequence of the injection…The solution…consisted of two drachms of muriate, and two scruples of carbonate, of soda, to sixty ounces of water" [11] . Converting these apothecary weights and avoirdupois volume to their metric equivalents, the solution would be hypotonic at 185.2 mM and also strongly alkaline, likely accounting for its good short-term results but poor long-term success. His remarkable discovery lit up the "message boards" of journals such as The Lancet, which was flooded with multiple reports of cholera therapies. This extraordinary discovery would not come into widespread use until the early 20th century, when improved understanding of blood electrolyte composition, intravascular volume, and intravenous fluid delivery enabled its successful implementation [12] , in particular by Leonard Rogers [13] . It was not until the 1940s, however, when the deeper understanding of blood electrolyte composition and whole body fluid and electrolyte dynamics enabled the safe and effective delivery of scientifically based intravenous fluid and electrolyte therapy [14] [15] [16] eventuating in the development of modern intravenous solutions (see [17] for a fascinating and detailed history). By 1957, numerous therapies had been proposed, as chronicled by Pollitzer, whose encyclopedic descriptions of therapies included serum, antibiotics [18, 19] , bacteriophages, essential oils, and kaolin, before his lengthy description of infusion therapy [20] . Oral fluids, regarded mostly as palliative, were not considered to be first-line therapy at that time.
Over time, the public works projects aimed at improving the quality of drinking water and disposing of sewage combined with improvements in intravenous therapy brought an end to sporadic and pandemic cholera in the developed world. These changes, however, did not occur as rapidly in the developing world, in which cholera remains a major public health challenge.
This divergence was addressed by the next advance was the discovery by Robert Crane in 1960 (first published in full in 1962) that luminal sodium ions increased the rate of transport of glucose in rat ileum [21, 22] work that was foundational for the study of ion cotransport mechanisms. This in turn was followed in 1968 by the publication of numerous studies conducted in India and Pakistan that reported that glucose-containing solutions perfused in the intestine via a long tube or consumed orally substantially decreased stool volume, documenting the efficacy of ORS in epidemic cholera. Since then, many publications have documented refinements of the original sodium-glucose-containing solution by adding organic components such as amino acids [23] or fermentable polymers such as resistant starch with further improvement on recovery times and treatment success [1, [24] [25] [26] [27] . At present, the main obstacles to the effective deployment of ORS therapy sadly arise mostly from societal and political, and not from medical barriers [28] .
The studies of glucose cotransport were followed by the discovery and cloning of the Na + :glucose cotransporter SGLT1 by Ernest Wright followed by the cloning and characterization of cotransporters for many nutrients and ions, which has increased knowledge of fundamental membrane transport [29] and has also led to the development of SGLT2 inhibitors for diabetes [30, 31] .
Along with ORS, research on cholera has also yielded valuable dividends in terms of the discovery of bacterial enterotoxins and their mechanism of action. The discovery of cholera exotoxin has been attributed to Dr. S. N. De, who reported in 1959 that sterile filtrates of Vibrio cholerae induced fluid secretion in; perfused rabbit jejunal loops [32, 33] . The next major basic scientific advance was the discovery in 1971 by Schafer et al. in 1970 [34] that cholera toxin increased intestinal cAMP levels, with publications in the following year by two groups at Harvard documenting that cholera toxin-induced adenylate cyclase to generate cAMP [35, 36] , which provided the foundation for understanding the mechanism of exotoxin-induced intestinal fluid secretion. This line of investigation eventuated in the discovery that adenylate cyclase 6 is specifically induced by cholera toxin, providing a plausible target for translational studies [37, 38] . Another offshoot was the development of small molecule inhibitors of the cystic fibrosis transmembrane regulator (CFTR) anion channel that have been useful experimental tools but have not yet been translated into mainstream clinical use for toxigenic diarrhea [39, 40] . Although the original hope was to find interventions that decreased fluid secretion, the discovery of the mechanism of action of cholera toxin has been translated into a class of drugs, the guanylate cyclase C (GC-C) receptor ligands, that effectively treat constipation in IBS patients by mimicking the closely related prosecretory actions of E. coli heat stable enterotoxin to produce in essence highly attenuated symptoms of cholera by inducing mucosal cGMP production [41] . These accomplishments are summarized in Table 1 .
In this issue of Digestive Diseases and Sciences, two giants of cholera therapy with ORS have summarized the field and their contributions to this area. Dr. Henry Binder has spent most of his long and distinguished career as an academic clinician-investigator studying the mechanisms of intestinal ion and water secretion. Of his many important discoveries, he was the first to describe the advantages of the inclusion fermentable carbohydrate polymers in ORS [42] . Dr. Zulfiqar A. Bhutta, who has spent most of his professional career studying the barriers that have prevented the full deployment of ORS in the developing world, provides a first-hand account of how ORS therapy is sadly underused despite its unparalleled safety, efficacy, and low cost [43] .
The two accompanying articles provide fascinating insight into the development of ORS and the many steps needed to promote its use in the developing world. I urge you to read these first-hand accounts of the development of what is considered to be "…potentially the most important medical advance this century" [44] . Michael Field and others The discovery of the mechanism of toxin-induced fluid secretion GC-C receptor ligands for functional bowel diseases and constipation
